REPORT ID 2361

United States Aurora Kinase B Market Report 2017

Publish Date
8-Dec-17
Pages
102
Format
Electronic (PDF)

In this report, the United States Aurora Kinase B market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:
    The West
    Southwest
    The Middle Atlantic
    New England
    The South
    The Midwest
with sales (volume), revenue (value), market share and growth rate of Aurora Kinase B in these regions, from 2012 to 2022 (forecast).

United States Aurora Kinase B market competition by top manufacturers/players, with Aurora Kinase B sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    AbbVie Inc
    Advenchen Laboratories LLC
    Aeterna Zentaris Inc
    Amgen Inc
    AstraZeneca Plc
    Chipscreen Biosciences Ltd
    Cielo Therapeutics Inc
    Sanofi
    Sareum Holdings Plc

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    AZD-2811
    CS-2164
    Danusertib
    Ilorasertib
    NMI-900
    Others
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Anaplastic Large Cell Lymphoma
    Kidney Cancer
    Lung Cancer
    Prostate Cancer
    Others

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

United States Aurora Kinase B Market Report 2017
1 Aurora Kinase B Overview
    1.1 Product Overview and Scope of Aurora Kinase B
    1.2 Classification of Aurora Kinase B by Product Category
        1.2.1 United States Aurora Kinase B Market Size (Sales Volume) Comparison by Type (2012-2022)
        1.2.2 United States Aurora Kinase B Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
        1.2.3 AZD-2811
        1.2.4 CS-2164
        1.2.5 Danusertib
        1.2.6 Ilorasertib
        1.2.7 NMI-900
        1.2.8 Others
    1.3 United States Aurora Kinase B Market by Application/End Users
        1.3.1 United States Aurora Kinase B Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
        1.3.2 Anaplastic Large Cell Lymphoma
        1.3.3 Kidney Cancer
        1.3.4 Lung Cancer
        1.3.5 Prostate Cancer
        1.3.6 Others
    1.4 United States Aurora Kinase B Market by Region
        1.4.1 United States Aurora Kinase B Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 The West Aurora Kinase B Status and Prospect (2012-2022)
        1.4.3 Southwest Aurora Kinase B Status and Prospect (2012-2022)
        1.4.4 The Middle Atlantic Aurora Kinase B Status and Prospect (2012-2022)
        1.4.5 New England Aurora Kinase B Status and Prospect (2012-2022)
        1.4.6 The South Aurora Kinase B Status and Prospect (2012-2022)
        1.4.7 The Midwest Aurora Kinase B Status and Prospect (2012-2022)
    1.5 United States Market Size (Value and Volume) of Aurora Kinase B (2012-2022)
        1.5.1 United States Aurora Kinase B Sales and Growth Rate (2012-2022)
        1.5.2 United States Aurora Kinase B Revenue and Growth Rate (2012-2022)

2 United States Aurora Kinase B Market Competition by Players/Suppliers
    2.1 United States Aurora Kinase B Sales and Market Share of Key Players/Suppliers (2012-2017)
    2.2 United States Aurora Kinase B Revenue and Share by Players/Suppliers (2012-2017)
    2.3 United States Aurora Kinase B Average Price by Players/Suppliers (2012-2017)
    2.4 United States Aurora Kinase B Market Competitive Situation and Trends
        2.4.1 United States Aurora Kinase B Market Concentration Rate
        2.4.2 United States Aurora Kinase B Market Share of Top 3 and Top 5 Players/Suppliers
        2.4.3 Mergers & Acquisitions, Expansion in United States Market
    2.5 United States Players/Suppliers Aurora Kinase B Manufacturing Base Distribution, Sales Area, Product Type

3 United States Aurora Kinase B Sales (Volume) and Revenue (Value) by Region (2012-2017)
    3.1 United States Aurora Kinase B Sales and Market Share by Region (2012-2017)
    3.2 United States Aurora Kinase B Revenue and Market Share by Region (2012-2017)
    3.3 United States Aurora Kinase B Price by Region (2012-2017)

4 United States Aurora Kinase B Sales (Volume) and Revenue (Value) by Type (Product Category) (2012-2017)
    4.1 United States Aurora Kinase B Sales and Market Share by Type (Product Category) (2012-2017)
    4.2 United States Aurora Kinase B Revenue and Market Share by Type (2012-2017)
    4.3 United States Aurora Kinase B Price by Type (2012-2017)
    4.4 United States Aurora Kinase B Sales Growth Rate by Type (2012-2017)

5 United States Aurora Kinase B Sales (Volume) by Application (2012-2017)
    5.1 United States Aurora Kinase B Sales and Market Share by Application (2012-2017)
    5.2 United States Aurora Kinase B Sales Growth Rate by Application (2012-2017)
    5.3 Market Drivers and Opportunities

6  United States Aurora Kinase B Players/Suppliers Profiles and Sales Data
    6.1 AbbVie Inc
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Aurora Kinase B Product Category, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 AbbVie Inc Aurora Kinase B Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Advenchen Laboratories LLC
        6.2.2 Aurora Kinase B Product Category, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Advenchen Laboratories LLC Aurora Kinase B Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Aeterna Zentaris Inc
        6.3.2 Aurora Kinase B Product Category, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Aeterna Zentaris Inc Aurora Kinase B Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Amgen Inc
        6.4.2 Aurora Kinase B Product Category, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Amgen Inc Aurora Kinase B Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 AstraZeneca Plc
        6.5.2 Aurora Kinase B Product Category, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 AstraZeneca Plc Aurora Kinase B Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Chipscreen Biosciences Ltd
        6.6.2 Aurora Kinase B Product Category, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Chipscreen Biosciences Ltd Aurora Kinase B Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Cielo Therapeutics Inc
        6.7.2 Aurora Kinase B Product Category, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Cielo Therapeutics Inc Aurora Kinase B Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Sanofi
        6.8.2 Aurora Kinase B Product Category, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Sanofi Aurora Kinase B Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 Sareum Holdings Plc
        6.9.2 Aurora Kinase B Product Category, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Sareum Holdings Plc Aurora Kinase B Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview

7 Aurora Kinase B Manufacturing Cost Analysis
    7.1 Aurora Kinase B Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Aurora Kinase B

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Aurora Kinase B Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Aurora Kinase B Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 United States Aurora Kinase B Market Size (Value and Volume) Forecast (2017-2022)
    11.1 United States Aurora Kinase B Sales Volume, Revenue Forecast (2017-2022)
    11.2 United States Aurora Kinase B Sales Volume Forecast by Type (2017-2022)
    11.3 United States Aurora Kinase B Sales Volume Forecast by Application (2017-2022)
    11.4 United States Aurora Kinase B Sales Volume Forecast by Region (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer